Heidrun Flaadt is one of 16 Women in Healthcare Innovation 2021. She received this recognition from the Innovation Office, University of Basel, for her work as director of the Center of Advanced Studies on Entrepreneurship in BioMedicine (CASE BioMed), Faculty of Biomedical Sciences at USI.
The last copies of the 1st edition of the accompanying book to the Bio- and MedTech Business Programs, which differs from the 2nd edition only in a chapter on the new Medical Device Regulations (MDR), are given at half price (95.—CHF). In case of interest, please contact: Heidrun.Flaadt@usi.ch.
HELIX HUB convinces through its architecture and design because innovation needs inspiration. It offers state-of-the-art equipment and the excellence of an all-round carefree package. Contact: Elsa Schnaitmann, elsa.schnaitmann@helix.life
Amal Therapeutics, a spin-off of the University of Geneva which was founded by the BioBusiness alumna Dr. Madiha Derouazi, was acquired by Boehringer Ingelheim for up to €425 Million. During the BioBusiness week, Madiha was introduced to the Helsinn Investment Fund, which invested in the start-up.
My expectations were sky-high for Lugano - many founder-friends mentioned your program as the best-learning experiences in Switzerland (with a crazy amount of competition). You fully delivered - it was really a fantastic learning experience and I loved it!
